What retatrutide changed early and what built over time

What retatrutide changed during the first months

Eli Lilly followed retatrutide treatment to learn how weight and sugar changes developed over time. Phase 2, the middle tests, found early weight loss that continued through 48 weeks.

With 12 milligrams, average weight loss reached about 8–10% by week 12 in the obesity study. Loss reached 17–18% by week 24 and 24.2% by week 48 ^[1], so the full change took time.

Separate Phase 2 studies found better sugar control and less liver fat by week 24 ^[2][5]. These were measured changes, rather than promises about when you would feel different.

After a ~6-day period, blood still held half the drug in the early study ^[4]. Weekly injections led to more settled blood levels after 4–5 weeks, helping explain steadier effects between shots.

Will your weight stay lower after retatrutide stops? No stopping results have been published for retatrutide, so evidence about weight returning comes from related medicines.

How Phase 2 middle tests measured weight week by week

In the 48-week Phase 2 middle study, doctors followed 338 adults with obesity ^[1]. The group receiving 12 milligram weekly shots lost weight early and kept losing through later visits.

Weeks 1–4: Amounts rose gradually while hunger fell and early stomach trouble began to ease. The shots hadn't yet reached 12 milligrams, so the first changes weren't measured at the final amount.

Weeks 4–12: Weight continued falling as drug levels in blood became more even between injections. By week 12, people working toward 12 milligrams had lost about 8–10% of their starting weight on average.

Weeks 12–24: The fastest weight loss occurred during this part of the trial. Average loss reached about 17–18% by week 24, before the final study visit.

Weeks 24–48: Weight loss slowed but continued through the end of treatment. Doctors measured the final average loss of 24.2% at week 48, well after the early changes.

Across 48 weeks, the 4 milligram group lost less than groups receiving larger amounts. Average loss was 17.3% with 8 milligrams and 24.2% with 12 milligrams ^[1], all under medical checks.

Phase 3, larger tests, found loss of 15.3% with 12 milligrams over 40 weeks in type 2 diabetes ^[12]. That was less than Phase 2 obesity loss; different study lengths and diabetes itself can limit your comparison.

When blood tests and scans showed changes beyond weight

A Phase 2 middle test followed 281 adults with type 2 diabetes for 36 weeks ^[2]. With 12 milligrams, blood tests showed better sugar control by 24 weeks, with most of the improvement already reached.

Better control remained at 36 weeks rather than disappearing after week 24. Those checks can't establish when you would notice a change in how you feel.

The liver study followed 98 people over 48 weeks ^[5]. With 12 milligrams, liver fat fell 82.4% by 24 weeks and continued falling by 48 weeks.

Most fat loss came before week 24, with a smaller further loss through week 48. Separately, by 24 weeks, 86% receiving 12 milligrams had normal liver-fat levels, meaning less than 5% fat ^[5].

Across these studies, the largest changes came by week 24, with smaller further changes through week 48. Blood levels halve over ~6 days and settle after 4–5 weeks of weekly shots ^[4], without predicting your own results.

What other medicines showed about hunger and weight after stopping

People regained substantial weight after liraglutide, semaglutide, or tirzepatide ended in a 2025 study ^[7]. The study didn't follow stopping retatrutide, so it raises a concern without giving you a direct answer.

A 2026 review also described regain after medicines acting on a hunger hormone ^[13]. Retatrutide adds glucagon's help with calorie burning, but proof that this keeps weight off after stopping remained limited.

Another 2026 review examined why hunger rises and calorie burning falls after related medicines stop ^[14]. Without treatment holding those changes in check, the body's tendency to regain excess weight returns.

Retatrutide's added hormone action might help, but no published trial has shown that it prevents weight returning. A possible benefit isn't the same as a lasting benefit measured in people.

In 2026, both the timing of weight loss and life after treatment matter to your choices. Retatrutide results explains the losses measured during treatment and the lack of findings afterward.

Further TRIUMPH follow-up is expected to examine stopping; Retatrutide research explains the trials. Until those results appear, large losses during injections can't promise that your weight will stay lower afterward.

What falling retatrutide levels cannot predict about returning hunger

After roughly a 6-day wait, blood still holds half the retatrutide ^[4], which helps explain weekly trial shots. After 4–5 weeks of weekly treatment, blood levels follow a repeating rise and fall.

Some related drugs leave blood sooner and were tested with daily injections. Retatrutide stays in your blood for a time after weekly injections end.

After 3–5 falls to half the previous amount, blood levels are expected to become very low, within 18–30 days. As less drug remains, hunger may return and food may pass through your stomach at its usual speed.

Lab findings ^[3] and Phase 1b early blood checks ^[4] suggest the drug's effects would largely fade within 4–6 weeks. This is an estimate from laboratory and blood checks, not a measured date for your hunger to return.

Very low blood levels and fully faded effects needn't occur on the same day. Neither estimate tells you when weight would return, because retatrutide's own stopping study results haven't been published.